Serhiy Hnatyshyn
Bristol-Myers Squibb (Germany), Bristol-Myers Squibb (United States)
Papers
2
Total Citations
171
H-Index
2
About
Serhiy Hnatyshyn is a pharmaceutical scientist whose research has made significant contributions to the field of drug metabolism and pharmacokinetics, with a particular focus on developing automated analytical workflows to accelerate early-stage drug discovery. His work centers on leveraging liquid chromatography-mass spectrometry (LC-MS) technologies to evaluate the metabolic stability of drug candidates, a critical factor in determining their viability as therapeutic agents. Hnatyshyn's most influential contribution, his 2008 paper on automated LC-MS processes for determining metabolic stability half-life and intrinsic clearance via substrate depletion, has garnered 134 citations, reflecting its broad adoption across the pharmaceutical research community. This work, alongside his 2007 introduction of the high-throughput MetFast assay (37 citations), established robust, scalable methodologies for assessing how drug candidates are processed by liver microsomes and cytochrome P450 enzymes — insights essential for predicting first-pass metabolism in humans. Together, these contributions have helped streamline pharmaceutical property profiling pipelines, enabling researchers to more efficiently triage drug candidates and reduce attrition in later development stages. His work remains a valuable reference for scientists navigating the complex intersection of analytical chemistry and drug development.
Research Focus
Key Achievements
Top Papers
- 1
- 2